Tempus AI

Tempus AI's 15min chart indicates RSI Overbought, KDJ Death Cross.

Tempus CEO on AI in Healthcare

Tempus AI's Valuation: Is its Price Reflective of its AI Healthcare Story?

Tempus AI shares surge 13.93% premarket after record $1.1B contract value and strong Q4 sales growth with pharma partnerships.

Tempus AI Sees Revenue Soar 83% YoY to $1.27 Billion in Preliminary 2025 Results

Catalyst<ul> <li>A MACD Golden Cross occurred on January 6, indicating strong bullish momentum for TEM.</li></ul>Risk<ul> <li>Fund flows show negative trends across most size buckets except for Large orders, signaling overall outflows and potential bearish pressure.</li> <li>Fundamental factors including ROA, net profit margin, and asset-MV ratios indicate underlying financial challenges for the company.</li></ul>

Key Factors

Tempus AI (TEM) reported preliminary 2025 revenue of $1.27 billion, an 83% year-over-year increase driven by a 111% surge in diagnostics revenue to $955 million and 31% growth in data and applications revenue to $316 million. The company announced record total contract value (TCV) exceeding $1.1 billion as of December 31, 2025, fueled by data agreements with over 70 pharmaceutical and biotech firms including AstraZeneca and Pfizer. Tempus AI's stock surged 10.13% premarket following the results, with CEO Eric Lefkofsky highlighting AI as a growth catalyst and CFO emphasizing strong customer retention and expansion of existing client relationships.

TEM News